ID   ATF2_HUMAN              Reviewed;         505 AA.
AC   P15336; A1L3Z2; A4D7U4; A4D7U5; A4D7V1; D3DPE9; G8JLM5; Q13000; Q3B7B7;
AC   Q4ZFU9; Q53RY2; Q8TAR1; Q96JT8;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 4.
DT   18-JUN-2025, entry version 242.
DE   RecName: Full=Cyclic AMP-dependent transcription factor ATF-2;
DE            Short=cAMP-dependent transcription factor ATF-2;
DE   AltName: Full=Activating transcription factor 2;
DE   AltName: Full=Cyclic AMP-responsive element-binding protein 2;
DE            Short=CREB-2;
DE            Short=cAMP-responsive element-binding protein 2;
DE   AltName: Full=HB16;
DE   AltName: Full=cAMP response element-binding protein CRE-BP1;
GN   Name=ATF2; Synonyms=CREB2, CREBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=2529117; DOI=10.1002/j.1460-2075.1989.tb03610.x;
RA   Maekawa T., Sakura H., Kanei-Ishii C., Sudo T., Yoshimura T., Fujisawa J.,
RA   Yoshida M., Ishii S.;
RT   "Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP
RT   response element in brain.";
RL   EMBO J. 8:2023-2028(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Thymus;
RX   PubMed=9058782;
RA   Yang L., Lanier E.R., Kraig E.;
RT   "Identification of a novel, spliced variant of CREB that is preferentially
RT   expressed in the thymus.";
RL   J. Immunol. 158:2522-2525(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8).
RC   TISSUE=Myometrium;
RX   PubMed=11932306; DOI=10.1210/jcem.87.4.8360;
RA   Bailey J., Phillips R.J., Pollard A.J., Gilmore K., Robson S.C.,
RA   Europe-Finner G.N.;
RT   "Characterization and functional analysis of cAMP response element
RT   modulator protein and activating transcription factor 2 (ATF2) isoforms in
RT   the human myometrium during pregnancy and labor: identification of a novel
RT   ATF2 species with potent transactivation properties.";
RL   J. Clin. Endocrinol. Metab. 87:1717-1728(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 5; 6 AND 7).
RA   von Hippel A.C.;
RT   "Homo sapiens activating transcription factor 2 (ATF2) mRNA splice
RT   variant.";
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 211-505 (ISOFORMS 1/2).
RX   PubMed=2320002; DOI=10.1128/mcb.10.4.1347-1357.1990;
RA   Kara C.J., Liou H.-C., Ivashkiv L.B., Glimcher L.H.;
RT   "A cDNA for a human cyclic AMP response element-binding protein which is
RT   distinct from CREB and expressed preferentially in brain.";
RL   Mol. Cell. Biol. 10:1347-1357(1990).
RN   [9]
RP   PHOSPHORYLATION BY CAMK4.
RX   PubMed=8855261; DOI=10.1073/pnas.93.20.10803;
RA   Enslen H., Tokumitsu H., Stork P.J., Davis R.J., Soderling T.R.;
RT   "Regulation of mitogen-activated protein kinases by a calcium/calmodulin-
RT   dependent protein kinase cascade.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10803-10808(1996).
RN   [10]
RP   PHOSPHORYLATION AT THR-69 AND THR-71.
RX   PubMed=9430721; DOI=10.1074/jbc.273.3.1741;
RA   Enslen H., Raingeaud J., Davis R.J.;
RT   "Selective activation of p38 mitogen-activated protein (MAP) kinase
RT   isoforms by the MAP kinase kinases MKK3 and MKK6.";
RL   J. Biol. Chem. 273:1741-1748(1998).
RN   [11]
RP   INTERACTION WITH UTF1.
RX   PubMed=9748258; DOI=10.1074/jbc.273.40.25840;
RA   Fukushima A., Okuda A., Nishimoto M., Seki N., Hori T.A., Muramatsu M.;
RT   "Characterization of functional domains of an embryonic stem cell
RT   coactivator UTF1 which are conserved and essential for potentiation of ATF-
RT   2 activity.";
RL   J. Biol. Chem. 273:25840-25849(1998).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION, AND MUTAGENESIS OF THR-69
RP   AND THR-71.
RX   PubMed=10821277; DOI=10.1038/35012097;
RA   Kawasaki H., Schiltz L., Chiu R., Itakura K., Taira K., Nakatani Y.,
RA   Yokoyama K.K.;
RT   "ATF-2 has intrinsic histone acetyltransferase activity which is modulated
RT   by phosphorylation.";
RL   Nature 405:195-200(2000).
RN   [13]
RP   PHOSPHORYLATION AT THR-69 AND THR-71.
RX   PubMed=12110590; DOI=10.1093/emboj/cdf361;
RA   Ouwens D.M., de Ruiter N.D., van der Zon G.C., Carter A.P., Schouten J.,
RA   van der Burgt C., Kooistra K., Bos J.L., Maassen J.A., van Dam H.;
RT   "Growth factors can activate ATF2 via a two-step mechanism: phosphorylation
RT   of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-
RT   p38.";
RL   EMBO J. 21:3782-3793(2002).
RN   [14]
RP   PHOSPHORYLATION AT SER-62 AND THR-73, AND SUBCELLULAR LOCATION.
RX   PubMed=15105425; DOI=10.1074/jbc.m401009200;
RA   Sevilla A., Santos C.R., Vega F.M., Lazo P.A.;
RT   "Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional
RT   activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with
RT   JNK.";
RL   J. Biol. Chem. 279:27458-27465(2004).
RN   [15]
RP   FUNCTION, INTERACTION WITH NBN AND MRE11, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT SER-490 AND SER-498.
RX   PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015;
RA   Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.;
RT   "ATM-dependent phosphorylation of ATF2 is required for the DNA damage
RT   response.";
RL   Mol. Cell 18:577-587(2005).
RN   [16]
RP   ACETYLATION AT LYS-357 AND LYS-374, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=17590016; DOI=10.1021/bi7000054;
RA   Karanam B., Wang L., Wang D., Liu X., Marmorstein R., Cotter R., Cole P.A.;
RT   "Multiple roles for acetylation in the interaction of p300 HAT with
RT   ATF-2.";
RL   Biochemistry 46:8207-8216(2007).
RN   [17]
RP   REVIEW.
RX   PubMed=18677098; DOI=10.4161/cc.6388;
RA   Bhoumik A., Ronai Z.;
RT   "ATF2: a transcription factor that elicits oncogenic or tumor suppressor
RT   activities.";
RL   Cell Cycle 7:2341-2345(2008).
RN   [18]
RP   FUNCTION, INTERACTION WITH CUL3 AND KAT5, AND SUBCELLULAR LOCATION.
RX   PubMed=18397884; DOI=10.1074/jbc.m802030200;
RA   Bhoumik A., Singha N., O'Connell M.J., Ronai Z.A.;
RT   "Regulation of TIP60 by ATF2 modulates ATM activation.";
RL   J. Biol. Chem. 283:17605-17614(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-69 AND SER-112, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [22]
RP   PHOSPHORYLATION AT THR-69; THR-71; SER-121; SER-340 AND SER-367, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19176525; DOI=10.1074/jbc.m808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-69; THR-71 AND SER-112, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-69; THR-71; SER-112 AND
RP   THR-116, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   PHOSPHORYLATION AT THR-71, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-71.
RX   PubMed=21098032; DOI=10.1074/jbc.m110.166009;
RA   Wang L., Payton R., Dai W., Lu L.;
RT   "Hyperosmotic stress-induced ATF-2 activation through Polo-like kinase 3 in
RT   human corneal epithelial cells.";
RL   J. Biol. Chem. 286:1951-1958(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-69; THR-71; SER-90 AND
RP   SER-112, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HK1/VDAC1 COMPLEX, AND
RP   PHOSPHORYLATION AT THR-52.
RX   PubMed=22304920; DOI=10.1016/j.cell.2012.01.016;
RA   Lau E., Kluger H., Varsano T., Lee K., Scheffler I., Rimm D.L., Ideker T.,
RA   Ronai Z.A.;
RT   "PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while
RT   blocking its apoptotic function at mitochondria.";
RL   Cell 148:543-555(2012).
RN   [28]
RP   SUBCELLULAR LOCATION, NUCLEAR EXPORT SIGNAL, INTERACTION WITH XPO1, AND
RP   HETERODIMERIZATION WITH JUN.
RX   PubMed=22275354; DOI=10.1074/jbc.m111.294272;
RA   Hsu C.C., Hu C.D.;
RT   "Critical role of N-terminal end-localized nuclear export signal in
RT   regulation of activating transcription factor 2 (ATF2) subcellular
RT   localization and transcriptional activity.";
RL   J. Biol. Chem. 287:8621-8632(2012).
RN   [29]
RP   REVIEW.
RX   PubMed=22685333; DOI=10.1242/jcs.095000;
RA   Lau E., Ronai Z.A.;
RT   "ATF2-at the crossroad of nuclear and cytosolic functions.";
RL   J. Cell Sci. 125:2815-2824(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62; THR-69; THR-71; SER-112
RP   AND SER-136, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-112; SER-328; SER-442 AND
RP   SER-446, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   STRUCTURE BY NMR OF 19-56.
RX   PubMed=10092462; DOI=10.1006/jmbi.1999.2620;
RA   Nagadoi A., Nakazawa K., Uda H., Okuno K., Maekawa T., Ishii S.,
RA   Nishimura Y.;
RT   "Solution structure of the transactivation domain of ATF-2 comprising a
RT   zinc finger-like subdomain and a flexible subdomain.";
RL   J. Mol. Biol. 287:593-607(1999).
RN   [33]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-352.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Transcriptional activator which regulates the transcription
CC       of various genes, including those involved in anti-apoptosis, cell
CC       growth, and DNA damage response. Dependent on its binding partner,
CC       binds to CRE (cAMP response element) consensus sequences (5'-TGACGTCA-
CC       3') or to AP-1 (activator protein 1) consensus sequences (5'-TGACTCA-
CC       3'). In the nucleus, contributes to global transcription and the DNA
CC       damage response, in addition to specific transcriptional activities
CC       that are related to cell development, proliferation and death. In the
CC       cytoplasm, interacts with and perturbs HK1- and VDAC1-containing
CC       complexes at the mitochondrial outer membrane, thereby impairing
CC       mitochondrial membrane potential, inducing mitochondrial leakage and
CC       promoting cell death. The phosphorylated form (mediated by ATM) plays a
CC       role in the DNA damage response and is involved in the ionizing
CC       radiation (IR)-induced S phase checkpoint control and in the
CC       recruitment of the MRN complex into the IR-induced foci (IRIF).
CC       Exhibits histone acetyltransferase (HAT) activity which specifically
CC       acetylates histones H2B and H4 in vitro (PubMed:10821277). In concert
CC       with CUL3 and RBX1, promotes the degradation of KAT5 thereby
CC       attenuating its ability to acetylate and activate ATM. Can elicit
CC       oncogenic or tumor suppressor activities depending on the tissue or
CC       cell type. {ECO:0000269|PubMed:10821277, ECO:0000269|PubMed:15916964,
CC       ECO:0000269|PubMed:18397884, ECO:0000269|PubMed:22304920}.
CC   -!- SUBUNIT: Binds DNA as a dimer and can form a homodimer in the absence
CC       of DNA. Can form a heterodimer with JUN. Heterodimerization is
CC       essential for its transcriptional activity. Interacts with SMAD3 and
CC       SMAD4. Binds through its N-terminal region to UTF1 which acts as a
CC       coactivator of ATF2 transcriptional activity. Interacts with the
CC       HK1/VDAC1 complex. Interacts with NBN, MRE11, XPO1, KAT5 and CUL3.
CC       {ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:18397884,
CC       ECO:0000269|PubMed:22275354, ECO:0000269|PubMed:22304920,
CC       ECO:0000269|PubMed:9748258}.
CC   -!- INTERACTION:
CC       P15336; P15336: ATF2; NbExp=2; IntAct=EBI-1170906, EBI-1170906;
CC       P15336; P18847: ATF3; NbExp=5; IntAct=EBI-1170906, EBI-712767;
CC       P15336; P18848: ATF4; NbExp=2; IntAct=EBI-1170906, EBI-492498;
CC       P15336; P17544: ATF7; NbExp=4; IntAct=EBI-1170906, EBI-765623;
CC       P15336; O14867: BACH1; NbExp=3; IntAct=EBI-1170906, EBI-1263541;
CC       P15336; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-1170906, EBI-11524452;
CC       P15336; Q16520: BATF; NbExp=2; IntAct=EBI-1170906, EBI-749503;
CC       P15336; Q9NR55: BATF3; NbExp=5; IntAct=EBI-1170906, EBI-10312707;
CC       P15336; P53567: CEBPG; NbExp=3; IntAct=EBI-1170906, EBI-740209;
CC       P15336; Q7L2Z9: CENPQ; NbExp=5; IntAct=EBI-1170906, EBI-2350265;
CC       P15336; Q99966: CITED1; NbExp=2; IntAct=EBI-1170906, EBI-2624951;
CC       P15336; P35638: DDIT3; NbExp=2; IntAct=EBI-1170906, EBI-742651;
CC       P15336; Q96B26: EXOSC8; NbExp=3; IntAct=EBI-1170906, EBI-371922;
CC       P15336; P01100: FOS; NbExp=15; IntAct=EBI-1170906, EBI-852851;
CC       P15336; Q6FG41: FOS; NbExp=3; IntAct=EBI-1170906, EBI-10198738;
CC       P15336; P53539: FOSB; NbExp=5; IntAct=EBI-1170906, EBI-2806743;
CC       P15336; P15407: FOSL1; NbExp=3; IntAct=EBI-1170906, EBI-744510;
CC       P15336; P15408: FOSL2; NbExp=8; IntAct=EBI-1170906, EBI-3893419;
CC       P15336; P56524: HDAC4; NbExp=2; IntAct=EBI-1170906, EBI-308629;
CC       P15336; P05412: JUN; NbExp=22; IntAct=EBI-1170906, EBI-852823;
CC       P15336; P17275: JUNB; NbExp=6; IntAct=EBI-1170906, EBI-748062;
CC       P15336; P17535: JUND; NbExp=6; IntAct=EBI-1170906, EBI-2682803;
CC       P15336; Q9BVG8: KIFC3; NbExp=3; IntAct=EBI-1170906, EBI-2125614;
CC       P15336; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-1170906, EBI-14069005;
CC       P15336; Q68G74: LHX8; NbExp=3; IntAct=EBI-1170906, EBI-8474075;
CC       P15336; P45984: MAPK9; NbExp=9; IntAct=EBI-1170906, EBI-713568;
CC       P15336; O95644: NFATC1; NbExp=2; IntAct=EBI-1170906, EBI-6907210;
CC       P15336; O75928-2: PIAS2; NbExp=3; IntAct=EBI-1170906, EBI-348567;
CC       P15336; P78317: RNF4; NbExp=3; IntAct=EBI-1170906, EBI-2340927;
CC       P15336; Q6IQ16: SPOPL; NbExp=3; IntAct=EBI-1170906, EBI-2822161;
CC       P15336; Q15532: SS18; NbExp=2; IntAct=EBI-1170906, EBI-2560599;
CC       P15336; P63165: SUMO1; NbExp=6; IntAct=EBI-1170906, EBI-80140;
CC       P15336; A4PIW0: SYT-SSX2; NbExp=11; IntAct=EBI-1170906, EBI-6050533;
CC       P15336; Q99986: VRK1; NbExp=5; IntAct=EBI-1170906, EBI-1769146;
CC       P15336; Q8IUH5: ZDHHC17; NbExp=3; IntAct=EBI-1170906, EBI-524753;
CC       P15336; P0C746: HBZ; Xeno; NbExp=3; IntAct=EBI-1170906, EBI-10890294;
CC       P15336; Q9DGW5: MDV005; Xeno; NbExp=2; IntAct=EBI-1170906, EBI-10889526;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Mitochondrion outer membrane.
CC       Note=Shuttles between the cytoplasm and the nucleus and
CC       heterodimerization with JUN is essential for the nuclear localization.
CC       Localization to the cytoplasm is observed under conditions of cellular
CC       stress and in disease states. Localizes at the mitochondrial outer
CC       membrane in response to genotoxic stress. Phosphorylation at Thr-52 is
CC       required for its nuclear localization and negatively regulates its
CC       mitochondrial localization. Co-localizes with the MRN complex in the
CC       IR-induced foci (IRIF).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1;
CC         IsoId=P15336-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15336-2; Sequence=VSP_000587, VSP_000588;
CC       Name=3;
CC         IsoId=P15336-3; Sequence=VSP_045161;
CC       Name=4;
CC         IsoId=P15336-4; Sequence=VSP_046959;
CC       Name=5;
CC         IsoId=P15336-5; Sequence=VSP_046960;
CC       Name=6;
CC         IsoId=P15336-6; Sequence=VSP_046960, VSP_047593;
CC       Name=7;
CC         IsoId=P15336-7; Sequence=VSP_046960, VSP_047594, VSP_047595;
CC       Name=8; Synonyms=ATF2-small;
CC         IsoId=P15336-8; Sequence=VSP_047593;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with more abundant
CC       expression in the brain.
CC   -!- DOMAIN: The nuclear export signal 1 (N-NES) negatively regulates its
CC       nuclear localization and transcriptional activity.
CC   -!- PTM: Phosphorylation of Thr-69 by MAPK14 and MAPK11, and at Thr-71 by
CC       MAPK1/ERK2, MAPK3/ERK1, MAPK11, MAPK12 and MAPK14 in response to
CC       external stimulus like insulin causes increased transcriptional
CC       activity (PubMed:12110590, PubMed:9430721). Phosphorylated by PLK3
CC       following hyperosmotic stress (PubMed:21098032). Also phosphorylated
CC       and activated by JNK and CaMK4 (PubMed:8855261). ATM-mediated
CC       phosphorylation at Ser-490 and Ser-498 stimulates its function in DNA
CC       damage response (PubMed:15916964). Phosphorylation at Ser-62, Thr-73
CC       and Ser-121 activates its transcriptional activity (PubMed:15105425).
CC       Phosphorylation at Thr-69 or Thr-71 enhances acetylation of histones
CC       H2B and H4 (PubMed:10821277). {ECO:0000269|PubMed:10821277,
CC       ECO:0000269|PubMed:12110590, ECO:0000269|PubMed:15105425,
CC       ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:21098032,
CC       ECO:0000269|PubMed:8855261, ECO:0000269|PubMed:9430721}.
CC   -!- SIMILARITY: Belongs to the bZIP family. ATF subfamily. {ECO:0000305}.
CC   -!- CAUTION: Appears to have histone acetyltransferase (HAT) activity,
CC       specifically towards histones H2B and H4 in vitro (PubMed:10821277).
CC       However, it is not clear if this activity is genuine or caused by
CC       contamination with other histone acetyltransferases in the assay.
CC       {ECO:0000269|PubMed:10821277, ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAY17203.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAY17207.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/718/ATF2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X15875; CAA33886.1; -; mRNA.
DR   EMBL; U16028; AAB64017.1; -; mRNA.
DR   EMBL; AY029364; AAK55760.1; -; mRNA.
DR   EMBL; DQ003037; AAY17203.1; ALT_INIT; mRNA.
DR   EMBL; DQ003038; AAY17204.1; -; mRNA.
DR   EMBL; DQ003041; AAY17207.1; ALT_INIT; mRNA.
DR   EMBL; DQ003044; AAY17210.1; -; mRNA.
DR   EMBL; DQ003047; AAY17213.1; -; mRNA.
DR   EMBL; DQ003049; AAY17215.1; -; mRNA.
DR   EMBL; AC131958; AAX88876.1; -; Genomic_DNA.
DR   EMBL; AC074291; AAY15004.1; -; Genomic_DNA.
DR   EMBL; AC007435; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC096649; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471058; EAX11111.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11112.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11113.1; -; Genomic_DNA.
DR   EMBL; BC026175; AAH26175.1; -; mRNA.
DR   EMBL; BC107698; AAI07699.1; -; mRNA.
DR   EMBL; BC130335; AAI30336.1; -; mRNA.
DR   EMBL; BC130337; AAI30338.1; -; mRNA.
DR   EMBL; M31630; AAA35951.1; -; mRNA.
DR   CCDS; CCDS2262.1; -. [P15336-1]
DR   CCDS; CCDS58737.1; -. [P15336-4]
DR   CCDS; CCDS58738.1; -. [P15336-5]
DR   CCDS; CCDS58739.1; -. [P15336-3]
DR   PIR; S05380; S05380.
DR   RefSeq; NP_001243019.1; NM_001256090.2. [P15336-1]
DR   RefSeq; NP_001243020.1; NM_001256091.2. [P15336-5]
DR   RefSeq; NP_001243021.1; NM_001256092.2. [P15336-4]
DR   RefSeq; NP_001243022.1; NM_001256093.1.
DR   RefSeq; NP_001243023.1; NM_001256094.2. [P15336-3]
DR   RefSeq; NP_001871.2; NM_001880.3. [P15336-1]
DR   PDB; 1BHI; NMR; -; A=19-56.
DR   PDB; 1T2K; X-ray; 3.00 A; D=354-414.
DR   PDB; 4H36; X-ray; 3.00 A; B=48-55.
DR   PDB; 6ZQS; X-ray; 1.95 A; B=83-102.
DR   PDB; 6ZR5; X-ray; 2.70 A; C/D=20-58.
DR   PDBsum; 1BHI; -.
DR   PDBsum; 1T2K; -.
DR   PDBsum; 4H36; -.
DR   PDBsum; 6ZQS; -.
DR   PDBsum; 6ZR5; -.
DR   AlphaFoldDB; P15336; -.
DR   BMRB; P15336; -.
DR   SMR; P15336; -.
DR   BioGRID; 107776; 239.
DR   ComplexPortal; CPX-6406; bZIP transcription factor complex, ATF2-ATF2.
DR   ComplexPortal; CPX-6407; bZIP transcription factor complex, ATF2-ATF3.
DR   ComplexPortal; CPX-6408; bZIP transcription factor complex, ATF2-ATF4.
DR   ComplexPortal; CPX-6409; bZIP transcription factor complex, ATF2-ATF7.
DR   ComplexPortal; CPX-6412; bZIP transcription factor complex, ATF2-BACH1.
DR   ComplexPortal; CPX-6413; bZIP transcription factor complex, ATF2-BATF.
DR   ComplexPortal; CPX-6414; bZIP transcription factor complex, ATF2-BATF3.
DR   ComplexPortal; CPX-6415; bZIP transcription factor complex, ATF2-DDIT3.
DR   ComplexPortal; CPX-6416; bZIP transcription factor complex, ATF2-FOS.
DR   ComplexPortal; CPX-6417; bZIP transcription factor complex, ATF2-FOSL1.
DR   ComplexPortal; CPX-6418; bZIP transcription factor complex, ATF2-FOSL2.
DR   ComplexPortal; CPX-6419; bZIP transcription factor complex, ATF2-JDP2.
DR   ComplexPortal; CPX-6420; bZIP transcription factor complex, ATF2-JUN.
DR   ComplexPortal; CPX-6421; bZIP transcription factor complex, ATF2-JUNB.
DR   ComplexPortal; CPX-6422; bZIP transcription factor complex, ATF2-JUND.
DR   CORUM; P15336; -.
DR   DIP; DIP-632N; -.
DR   ELM; P15336; -.
DR   FunCoup; P15336; 6112.
DR   IntAct; P15336; 230.
DR   MINT; P15336; -.
DR   STRING; 9606.ENSP00000264110; -.
DR   ChEMBL; CHEMBL5291557; -.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   MoonProt; P15336; -.
DR   GlyCosmos; P15336; 9 sites, 2 glycans.
DR   GlyGen; P15336; 16 sites, 2 O-linked glycans (15 sites).
DR   iPTMnet; P15336; -.
DR   PhosphoSitePlus; P15336; -.
DR   BioMuta; ATF2; -.
DR   DMDM; 215274241; -.
DR   jPOST; P15336; -.
DR   MassIVE; P15336; -.
DR   PaxDb; 9606-ENSP00000264110; -.
DR   PeptideAtlas; P15336; -.
DR   ProteomicsDB; 34276; -.
DR   ProteomicsDB; 53131; -. [P15336-1]
DR   ProteomicsDB; 53132; -. [P15336-2]
DR   ProteomicsDB; 61652; -.
DR   ProteomicsDB; 650; -.
DR   ProteomicsDB; 651; -.
DR   ProteomicsDB; 73911; -.
DR   ProteomicsDB; 77009; -.
DR   Pumba; P15336; -.
DR   Antibodypedia; 3529; 2489 antibodies from 51 providers.
DR   DNASU; 1386; -.
DR   Ensembl; ENST00000264110.7; ENSP00000264110.2; ENSG00000115966.18. [P15336-1]
DR   Ensembl; ENST00000345739.9; ENSP00000340576.5; ENSG00000115966.18. [P15336-4]
DR   Ensembl; ENST00000392544.5; ENSP00000376327.1; ENSG00000115966.18. [P15336-1]
DR   Ensembl; ENST00000409499.5; ENSP00000386282.1; ENSG00000115966.18. [P15336-8]
DR   Ensembl; ENST00000409635.5; ENSP00000387093.1; ENSG00000115966.18. [P15336-4]
DR   Ensembl; ENST00000409833.5; ENSP00000386526.1; ENSG00000115966.18. [P15336-3]
DR   Ensembl; ENST00000426833.7; ENSP00000407911.3; ENSG00000115966.18. [P15336-5]
DR   GeneID; 1386; -.
DR   KEGG; hsa:1386; -.
DR   MANE-Select; ENST00000264110.7; ENSP00000264110.2; NM_001880.4; NP_001871.2.
DR   UCSC; uc002ujk.5; human. [P15336-1]
DR   AGR; HGNC:784; -.
DR   CTD; 1386; -.
DR   DisGeNET; 1386; -.
DR   GeneCards; ATF2; -.
DR   HGNC; HGNC:784; ATF2.
DR   HPA; ENSG00000115966; Low tissue specificity.
DR   MIM; 123811; gene.
DR   OpenTargets; ENSG00000115966; -.
DR   VEuPathDB; HostDB:ENSG00000115966; -.
DR   eggNOG; KOG1414; Eukaryota.
DR   GeneTree; ENSGT00940000156582; -.
DR   HOGENOM; CLU_1980813_0_0_1; -.
DR   InParanoid; P15336; -.
DR   OMA; YQTADKD; -.
DR   OrthoDB; 295274at2759; -.
DR   PAN-GO; P15336; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; P15336; -.
DR   PathwayCommons; P15336; -.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-9031628; NGF-stimulated transcription.
DR   Reactome; R-HSA-9633012; Response of EIF2AK4 (GCN2) to amino acid deficiency.
DR   Reactome; R-HSA-9707616; Heme signaling.
DR   SignaLink; P15336; -.
DR   SIGNOR; P15336; -.
DR   BioGRID-ORCS; 1386; 20 hits in 1196 CRISPR screens.
DR   ChiTaRS; ATF2; human.
DR   EvolutionaryTrace; P15336; -.
DR   GeneWiki; Activating_transcription_factor_2; -.
DR   GenomeRNAi; 1386; -.
DR   Pharos; P15336; Tbio.
DR   PRO; PR:P15336; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P15336; protein.
DR   Bgee; ENSG00000115966; Expressed in endothelial cell and 212 other cell types or tissues.
DR   ExpressionAtlas; P15336; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IDA:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:1902562; C:H4 histone acetyltransferase complex; IDA:ARUK-UCL.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ComplexPortal.
DR   GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB.
DR   GO; GO:0035497; F:cAMP response element binding; IDA:BHF-UCL.
DR   GO; GO:0008140; F:cAMP response element binding protein binding; IDA:BHF-UCL.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:MGI.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; TAS:Reactome.
DR   GO; GO:0044013; F:histone H2B acetyltransferase activity; IDA:ARUK-UCL.
DR   GO; GO:0010485; F:histone H4 acetyltransferase activity; IDA:ARUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043522; F:leucine zipper domain binding; IEA:Ensembl.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IMP:NTNU_SB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0021742; P:abducens nucleus development; IEA:Ensembl.
DR   GO; GO:0060612; P:adipose tissue development; IEA:Ensembl.
DR   GO; GO:1902742; P:apoptotic process involved in development; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0003360; P:brainstem development; IEA:Ensembl.
DR   GO; GO:0072740; P:cellular response to anisomycin; IEA:Ensembl.
DR   GO; GO:1990253; P:cellular response to leucine starvation; IDA:MGI.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0098586; P:cellular response to virus; IEA:Ensembl.
DR   GO; GO:0060245; P:detection of cell density; IEA:Ensembl.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:0021754; P:facial nucleus development; IEA:Ensembl.
DR   GO; GO:0003418; P:growth plate cartilage chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0003419; P:growth plate cartilage chondrocyte proliferation; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0021743; P:hypoglossal nucleus development; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl.
DR   GO; GO:0007254; P:JNK cascade; IEA:Ensembl.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; EXP:ComplexPortal.
DR   GO; GO:0060052; P:neurofilament cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0001865; P:NK T cell differentiation; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0038066; P:p38MAPK cascade; IEA:Ensembl.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:MGI.
DR   GO; GO:0110024; P:positive regulation of cardiac muscle myoblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:1902110; P:positive regulation of mitochondrial membrane permeability involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0032915; P:positive regulation of transforming growth factor beta2 production; IEA:Ensembl.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0006970; P:response to osmotic stress; IDA:UniProtKB.
DR   GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:ARUK-UCL.
DR   GO; GO:0007033; P:vacuole organization; IEA:Ensembl.
DR   GO; GO:0050872; P:white fat cell differentiation; IEA:Ensembl.
DR   CDD; cd14687; bZIP_ATF2; 1.
DR   CDD; cd12192; GCN4_cent; 1.
DR   FunFam; 1.20.5.170:FF:000010; Cyclic AMP-dependent transcription factor ATF-2; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 1.
DR   IDEAL; IID00441; -.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR046347; bZIP_sf.
DR   InterPro; IPR051027; bZIP_transcription_factors.
DR   InterPro; IPR016378; TF_CRE-BP1-typ.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR19304; CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN; 1.
DR   Pfam; PF00170; bZIP_1; 1.
DR   PIRSF; PIRSF003153; ATF2_CRE-BP1; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 1.
DR   SUPFAM; SSF57959; Leucine zipper domain; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 1.
DR   neXtProt; NX_P15336; -.
DR   PharmGKB; PA25084; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm;
KW   DNA damage; DNA-binding; Membrane; Metal-binding; Mitochondrion;
KW   Mitochondrion outer membrane; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Transcription;
KW   Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..505
FT                   /note="Cyclic AMP-dependent transcription factor ATF-2"
FT                   /id="PRO_0000076577"
FT   DOMAIN          352..415
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   ZN_FING         25..49
FT                   /note="C2H2-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          125..155
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          259..373
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          296..299
FT                   /note="Essential for its histone acetyltransferase
FT                   activity"
FT   REGION          354..374
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          380..408
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          425..472
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1..7
FT                   /note="Nuclear export signal 1 (N-NES)"
FT   MOTIF           405..414
FT                   /note="Nuclear export signal 2 (C-NES)"
FT   COMPBIAS        282..293
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        318..334
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        346..363
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        443..454
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        455..467
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         52
FT                   /note="Phosphothreonine; by PKC/PRKCH"
FT                   /evidence="ECO:0000269|PubMed:22304920"
FT   MOD_RES         62
FT                   /note="Phosphoserine; by VRK1"
FT                   /evidence="ECO:0000269|PubMed:15105425,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         69
FT                   /note="Phosphothreonine; by MAPK11 and MAPK14"
FT                   /evidence="ECO:0000269|PubMed:12110590,
FT                   ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:9430721,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         71
FT                   /note="Phosphothreonine; by MAPK1, MAPK3, MAPK11, MAPK12,
FT                   MAPK14 and PLK3"
FT                   /evidence="ECO:0000269|PubMed:12110590,
FT                   ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21098032,
FT                   ECO:0000269|PubMed:9430721, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         73
FT                   /note="Phosphothreonine; by VRK1"
FT                   /evidence="ECO:0000269|PubMed:15105425"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         112
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         116
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         121
FT                   /note="Phosphoserine; by PKC/PRKCA and PKC/PRKCB"
FT                   /evidence="ECO:0000269|PubMed:19176525"
FT   MOD_RES         136
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         340
FT                   /note="Phosphoserine; by PKC/PRKCA and PKC/PRKCB"
FT                   /evidence="ECO:0000269|PubMed:19176525"
FT   MOD_RES         357
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:17590016"
FT   MOD_RES         367
FT                   /note="Phosphoserine; by PKC/PRKCA and PKC/PRKCB"
FT                   /evidence="ECO:0000269|PubMed:19176525"
FT   MOD_RES         374
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:17590016"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         490
FT                   /note="Phosphoserine; by ATM"
FT                   /evidence="ECO:0000269|PubMed:15916964"
FT   MOD_RES         498
FT                   /note="Phosphoserine; by ATM"
FT                   /evidence="ECO:0000269|PubMed:15916964"
FT   VAR_SEQ         1..176
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9058782"
FT                   /id="VSP_000587"
FT   VAR_SEQ         1..66
FT                   /note="MKFKLHVNSARQYKDLWNMSDDKPFLCTAPGCGQRFTNEDHLAVHKHKHEMT
FT                   LKFGPARNDSVIVA -> MYCAWMWP (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_046959"
FT   VAR_SEQ         1..18
FT                   /note="Missing (in isoform 5, isoform 6 and isoform 7)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_046960"
FT   VAR_SEQ         34..394
FT                   /note="Missing (in isoform 6 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:11932306, ECO:0000303|Ref.4"
FT                   /id="VSP_047593"
FT   VAR_SEQ         177..185
FT                   /note="TSSDSSVII -> MSTAYFQMM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9058782"
FT                   /id="VSP_000588"
FT   VAR_SEQ         210..505
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_045161"
FT   VAR_SEQ         210..237
FT                   /note="PVPGPFPLLLHLPNGQTMPVAIPASITS -> SFDQSPWCLVFQESQVLPLP
FT                   NQYSQKQK (in isoform 7)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_047594"
FT   VAR_SEQ         238..505
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_047595"
FT   VARIANT         352
FT                   /note="D -> H (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035999"
FT   MUTAGEN         69
FT                   /note="T->A: Weak histone acetyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:10821277"
FT   MUTAGEN         71
FT                   /note="T->A: Impairs phosphorylation by PLK3. Weak histone
FT                   acetyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:10821277,
FT                   ECO:0000269|PubMed:21098032"
FT   MUTAGEN         121
FT                   /note="S->A: Reduced phosphorylation and repression of
FT                   c-Jun-mediated activation of transcription."
FT   CONFLICT        209
FT                   /note="V -> L (in Ref. 2; AAB64017)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        223
FT                   /note="N -> S (in Ref. 1; CAA33886 and 4;
FT                   AAY17203/AAY17207/AAY17215)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        311
FT                   /note="R -> L (in Ref. 2; AAB64017)"
FT                   /evidence="ECO:0000305"
FT   TURN            30..32
FT                   /evidence="ECO:0007829|PDB:1BHI"
FT   STRAND          35..38
FT                   /evidence="ECO:0007829|PDB:6ZR5"
FT   HELIX           39..49
FT                   /evidence="ECO:0007829|PDB:6ZR5"
FT   TURN            51..55
FT                   /evidence="ECO:0007829|PDB:1BHI"
FT   HELIX           91..100
FT                   /evidence="ECO:0007829|PDB:6ZQS"
FT   HELIX           355..412
FT                   /evidence="ECO:0007829|PDB:1T2K"
SQ   SEQUENCE   505 AA;  54537 MW;  0190EEFAEC8891A7 CRC64;
     MKFKLHVNSA RQYKDLWNMS DDKPFLCTAP GCGQRFTNED HLAVHKHKHE MTLKFGPARN
     DSVIVADQTP TPTRFLKNCE EVGLFNELAS PFENEFKKAS EDDIKKMPLD LSPLATPIIR
     SKIEEPSVVE TTHQDSPLPH PESTTSDEKE VPLAQTAQPT SAIVRPASLQ VPNVLLTSSD
     SSVIIQQAVP SPTSSTVITQ APSSNRPIVP VPGPFPLLLH LPNGQTMPVA IPASITSSNV
     HVPAAVPLVR PVTMVPSVPG IPGPSSPQPV QSEAKMRLKA ALTQQHPPVT NGDTVKGHGS
     GLVRTQSEES RPQSLQQPAT STTETPASPA HTTPQTQSTS GRRRRAANED PDEKRRKFLE
     RNRAAASRCR QKRKVWVQSL EKKAEDLSSL NGQLQSEVTL LRNEVAQLKQ LLLAHKDCPV
     TAMQKKSGYH TADKDDSSED ISVPSSPHTE AIQHSSVSTS NGVSSTSKAE AVATSVLTQM
     ADQSTEPALS QIVMAPSSQS QPSGS
//
